LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer

Mengxing Li, Suryavathi Viswanadhapalli, Bindu Santhamma, Uday P. Pratap, Yiliao Luo, Junhao Liu, Kristin A. Altwegg, Weiwei Tang, Zexuan Liu, Xiaonan Li, Behnam Ebrahimi, Hui Yan, Yi Zou, Swapna Konda, Gangadhara R. Sareddy, Zhenming Xu, Yidong Chen, Manjeet K. Rao, Andrew J. Brenner, Virginia G. KaklamaniRajeshwar R. Tekmal, Gulzar Ahmed, Ganesh V. Raj, Klaus J. Nickisch, Hareesh B. Nair, Ratna K. Vadlamudi

Producción científica: Articlerevisión exhaustiva

15 Citas (Scopus)


Histone deacetylase inhibitors (HDACi) are identified as novel therapeutic agents, however, recent clinical studies suggested that they are marginally effective in treating triple negative breast cancer (TNBC). Here, we show that first-in-class Leukemia Inhibitory Factor Receptor (LIFRα) inhibitor EC359 could enhance the therapeutic efficacy of HDACi against TNBC. We observed that both targeted knockdown of LIFR with CRISPR or treatment with EC359 enhanced the potency of four different HDACi in reducing cell viability, cell survival, and enhanced apoptosis compared to monotherapy in TNBC cells. RNA-seq studies demonstrated oncogenic/survival signaling pathways activated by HDACi were attenuated by the EC359 + HDACi therapy. Importantly, combination therapy potently inhibited the growth of TNBC patient derived explants, cell derived xenografts and patient-derived xenografts in vivo. Collectively, our results suggest that targeted inhibition of LIFR can enhance the therapeutic efficacy of HDACi in TNBC.

Idioma originalEnglish (US)
Número de artículo1235
PublicaciónCommunications Biology
EstadoPublished - dic 2021

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology
  • General Agricultural and Biological Sciences
  • Medicine (miscellaneous)


Profundice en los temas de investigación de 'LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer'. En conjunto forman una huella única.

Citar esto